Viking Therapeutics (STU:1VT) Total Payout Yield %: -0.30 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1VT Viking Therapeutics Inc STU:1VT
38 GF Score
Price €29.00
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics Total Payout Yield %?

Viking Therapeutics STU:1VT -2.36% 38 Total Payout Yield % is -0.30 as of Jul. 30, 2026. GuruFocus rates STU:1VT with a GF Score™ of 38/100. The stock has 3 warning signs investors should review.

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Viking Therapeutics's current Total Payout Yield % is -0.30%.


Viking Therapeutics Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Viking Therapeutics Total Payout Yield % Related Terms


Viking Therapeutics Total Payout Yield % Historical Data

* Premium members only.

The historical data trend for Viking Therapeutics's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics Total Payout Yield % Chart

Viking Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.96 -14.33 -13.21 0.00

Viking Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.23

STU:1VT vs DYN, CELC, RLAY: Total Payout Yield % Comparison

For the Biotechnology subindustry, Viking Therapeutics's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viking Therapeutics Total Payout Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Total Payout Yield % falls into.


STU:1VT
38GF Score
Viking Therapeutics Inc STU:1VT
Total Payout Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Viking Therapeutics's Total Payout Yield % for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 0 + 0) / 3527.014925
=0.00%

Viking Therapeutics's annualized Total Payout Yield % for the quarter that ended in Mar. 2026 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 10.057 + 0) * 4 / 3258.93928
=-1.23%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Yield % →
What does a Total Payout Yield % of -0.30 mean?
Viking Therapeutics (STU:1VT) has a Total Payout Yield % of -0.30 as of Jul. 30, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Viking Therapeutics and its competitors.
Is Viking Therapeutics' Total Payout Yield % too high?
Viking Therapeutics' current Total Payout Yield % is -0.30. Overall, Viking Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' Total Payout Yield % compare to DYN and CELC?
Viking Therapeutics' Total Payout Yield % of -0.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Biotechnology company?
A good Total Payout Yield % depends on the Biotechnology industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Viking Therapeutics and its competitors. Viking Therapeutics's current Total Payout Yield % is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (STU:1VT) has a current Total Payout Yield % of -0.30. The current Total Payout Yield % is -0.30. Viking Therapeutics' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For Viking Therapeutics (STU:1VT), the current Total Payout Yield % is -0.30 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Other Exchanges VKTX:USA1VKTX:Italy0VQA:UK
Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
38GF Score

Get the complete analysis for STU:1VT

Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.00
Price